In Brief: Ciba/Chiron's Aredia
Executive Summary
Ciba/Chiron's Aredia: Rates of "skeletal-related episodes" seen in first-line patients for prevention of bone metastases associated with multiple myeloma were 22% for Aredia compared to 33% for placebo. "The Pink Sheet" (July 31, p. 12) incorrectly reported the data presented to FDA's Oncologic Drugs Advisory Committee during a review of pamidronate July 24...